Keros Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Keros Therapeutics, Inc.

Keros Therapeutics, Inc. (KROS) is a clinical-stage biopharmaceutical company listed on the Nasdaq in the United States (United States) and headquartered in Lexington, Massachusetts. Founded in December 2015 and brought to the public markets in 2020, the company is built around a focused scientific thesis: modulating signaling in the transforming growth factor-beta (TGF-β) pathway, a family of proteins involved in red blood cell and platelet production, as well as the repair, growth, and maintenance of multiple tissues. For French-speaking investors, Keros should be viewed as a specialty biotech with no marketed products yet, but with a differentiated research platform and a highly targeted approach to diseases with significant unmet medical need. From an operating perspective, Keros has historically aimed at hematologic, pulmonary, and cardiovascular disorders, but in recent years it has sharpened its strategic priorities around a smaller set of programs. Like most development-stage biotech names, its business model is characterized by heavy R&D spending, a dependence on external capital, and valuation drivers that are primarily clinical, regulatory, and partnership-related rather than revenue-based. The company states that it was incorporated in 2015 and commenced operations in 2016, with its principal executive office still located in Lexington, Massachusetts. Keros’ current pipeline is centered on two principal candidates. The lead asset, rinvatercept (also referred to as KER-065 in some company materials), is being developed for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS). In March 2026, management said it expected to begin a Phase 2 DMD trial in the second quarter of 2026, and to engage regulators on the design of a Phase 2 ALS trial in the second half of 2026. The second major program, elritercept, is being developed for cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis. In competitive terms, Keros operates in highly crowded therapeutic areas, where larger, better-capitalized companies already have approved therapies or late-stage assets. Its differentiation lies in its proprietary understanding of TGF-β biology and in the potential for protein therapeutics to deliver disease-modifying benefit. A notable strategic move in 2025 was the termination of the cibotercept program in pulmonary arterial hypertension, allowing the company to redirect resources toward rinvatercept and its most promising opportunities. Recent highlights include first-quarter 2026 financial results released in May 2026, additional clinical data from the rinvatercept program presented in March 2026, and a collaboration announced with the Sean M. Healey & AMG Center for ALS. Overall, Keros remains a catalyst-driven small-cap biotech story: execution on clinical milestones, regulatory progress, and cash discipline will likely matter more than near-term commercial metrics.